Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations

Author： Schneider C.   Jick S. S.   Meier C. R.  

Publisher： Informa Healthcare

ISSN： 1473-0804

Source： Climacteric, Vol.12, Iss.5, 2009-10, pp. : 445-453

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT

By L’Hermite M.  

Climacteric, Vol. 16, Iss. 1, 2013-08 ,pp. : 44-53

Informa Healthcare

Access to resources Recommend Favorite

Aging, menopause, cardiovascular disease and HRT

By  

Climacteric, Vol. 12, Iss. 5, 2009-10 ,pp. : 368-377

Informa Healthcare

Access to resources Recommend Favorite

HRT and breast cancer risk: a realistic perspective

By Stevenson J. C.   Hodis H. N.   Pickar J. H.   Lobo R. A.  

Climacteric, Vol. 14, Iss. 6, 2011-12 ,pp. : 633-636

Informa Healthcare

Access to resources Recommend Favorite

HRT and breast cancer risk, what to advise?

By von Schoultz B.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 71, Iss. 2, 1997-02 ,pp. : 205-208

Elsevier

Access to resources Recommend Favorite

1 and 2 mg 17β-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women

By Stevenson J. C.   Rioux J. E.   Komer L.   Gelfand M.  

Climacteric, Vol. 8, Iss. 4, 2005-12 ,pp. : 352-359

Informa Healthcare

Access to resources Recommend Favorite